Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

Similar articles for PubMed (Select 25108081)

1.

Bone turnover markers as predictive indicators of outcome in patients with breast cancer and bone metastases treated with bisphosphonates: results from a 2-year multicentre observational study (ZOMAR study).

Barnadas A, Manso L, de la Piedra C, Meseguer C, Crespo C, Gómez P, Calvo L, Martinez P, Ruiz-Borrego M, Perelló A, Antón A, Codes M, Margelí M, Murias A, Salvador J, Seguí MÁ, de Juan A, Gavilá J, Luque M, Pérez D, Zamora P, Arizcuma A, Chacón JI, Heras L, Martin-Fernández M, Mahillo-Fernández I, Tusquets I.

Bone. 2014 Nov;68:32-40. doi: 10.1016/j.bone.2014.07.036. Epub 2014 Aug 7.

PMID:
25108081
2.

Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study.

de la Piedra C, Alcaraz A, Bellmunt J, Meseguer C, Gómez-Caamano A, Ribal MJ, Vázquez F, Anido U, Samper P, Esteban E, Álvarez-Ossorio JL, Lara PC, San José LA, Contreras JA, del Alba AG, González-Gragera B, Tabernero AJ, González-Enguita C, Fernández JM, García-Escudero A, Gómez-Veiga F, Méndez MJ, Segarra J, Virizuela JA, Carles J, Lassa A, Calderero V, Constela M, Delgado D, Mañas A, Murias A, Reynes G, Rodriguez B, Rubio G, Sánchez E, Unda M, Solsona E, Martínez-Javaloyas JM, Comet-Batlle J, Quicios C, Martín-Fernández M, Mahillo-Fernández I, Morote J.

Br J Cancer. 2013 Jun 25;108(12):2565-72. doi: 10.1038/bjc.2013.270. Epub 2013 May 30.

3.

Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid.

Pectasides D, Nikolaou M, Farmakis D, Kanakis I, Gaglia A, Kountourakis P, Karamanos NK, Economopoulos T, Raptis SA.

Anticancer Res. 2005 Mar-Apr;25(2B):1457-63.

4.

Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid.

Zhao X, Xu X, Zhang Q, Jia Z, Sun S, Zhang J, Wang B, Wang Z, Hu X.

BMC Cancer. 2011 Sep 22;11:403. doi: 10.1186/1471-2407-11-403.

5.

Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity.

Hirsh V, Major PP, Lipton A, Cook RJ, Langer CJ, Smith MR, Brown JE, Coleman RE.

J Thorac Oncol. 2008 Mar;3(3):228-36. doi: 10.1097/JTO.0b013e3181651c0e.

PMID:
18317064
6.

Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analyses.

Lipton A, Cook R, Brown J, Body JJ, Smith M, Coleman R.

Clin Oncol (R Coll Radiol). 2013 Apr;25(4):217-26. doi: 10.1016/j.clon.2012.11.004. Epub 2012 Dec 6.

PMID:
23219232
7.

Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.

Clemons MJ, Dranitsaris G, Ooi WS, Yogendran G, Sukovic T, Wong BY, Verma S, Pritchard KI, Trudeau M, Cole DE.

J Clin Oncol. 2006 Oct 20;24(30):4895-900. Epub 2006 Sep 25.

8.

Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.

Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, Saad F, Zheng M, Hei YJ, Seaman J, Cook R.

J Clin Oncol. 2005 Aug 1;23(22):4925-35. Epub 2005 Jun 27.

9.

Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study.

Alcaraz A, González-López R, Morote J, de la Piedra C, Meseguer C, Esteban E, Climent M, González-Gragera B, Alvarez-Ossorio JL, Chirivella I, Mellado B, Lara PC, Vázquez F, Contreras JA, Carles J, Murias A, Calderero V, Comet-Batlle J, González-Del Alba A, León-Mateos L, Mañas A, Segarra J, Lassa A, González-Enguita C, Méndez MJ, Samper P, Unda M, Mahillo-Fernández I, Bellmunt J; TUGAMO GROUP.

Br J Cancer. 2013 Jul 9;109(1):121-30. doi: 10.1038/bjc.2013.272. Epub 2013 Jun 25.

10.

Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.

Devogelaer JP, Sambrook P, Reid DM, Goemaere S, Ish-Shalom S, Collette J, Su G, Bucci-Rechtweg C, Papanastasiou P, Reginster JY.

Rheumatology (Oxford). 2013 Jun;52(6):1058-69. doi: 10.1093/rheumatology/kes410. Epub 2013 Jan 30.

11.

Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.

Lipton A, Cook RJ, Major P, Smith MR, Coleman RE.

Oncologist. 2007 Sep;12(9):1035-43.

12.

Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.

Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee KA, Zheng M, Hei YJ, Coleman RE.

J Natl Cancer Inst. 2005 Jan 5;97(1):59-69.

13.

Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases.

Generali D, Dovio A, Tampellini M, Tucci M, Tedoldi S, Torta M, Bonardi S, Allevi G, Aguggini S, Milani M, Harris AL, Bottini A, Dogliotti L, Angeli A, Berruti A.

Br J Cancer. 2008 Jun 3;98(11):1753-8. doi: 10.1038/sj.bjc.6604390. Epub 2008 May 27.

14.

A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events.

Addison CL, Bouganim N, Hilton J, Vandermeer L, Dent S, Amir E, Hopkins S, Kuchuk I, Segal R, Song X, Gertler S, Mazzarello S, Dranitsaris G, Ooi D, Pond G, Clemons M.

Breast Cancer Res Treat. 2014 Apr;144(3):615-24. doi: 10.1007/s10549-014-2906-x. Epub 2014 Mar 18.

15.

The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy.

Israeli RS, Rosenberg SJ, Saltzstein DR, Gottesman JE, Goldstein HR, Hull GW, Tran DN, Warsi GM, Lacerna LV.

Clin Genitourin Cancer. 2007 Mar;5(4):271-7.

PMID:
17553207
16.

Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid.

Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E, Brown JE, Coleman RE.

Cancer. 2008 Jul 1;113(1):193-201. doi: 10.1002/cncr.23529.

17.

[Efficacy of zoledronic acid combined with chemotherapy in treatment of skeletal metastases of non-small cell lung cancer and the bone metabolic markers].

Hu XY, Zou QF, Jin C, Li WD, Chen WS, Ma L.

Nan Fang Yi Ke Da Xue Xue Bao. 2010 Jun;30(6):1343-6. Chinese.

18.

Increases in bone turnover marker levels at an early phase after starting zoledronic acid predicts skeletal-related events in patients with prostate cancer with bone metastasis.

Izumi K, Mizokami A, Itai S, Shima T, Shigehara K, Miwa S, Maeda Y, Konaka H, Koh E, Namiki M.

BJU Int. 2012 Feb;109(3):394-400. doi: 10.1111/j.1464-410X.2011.10192.x. Epub 2011 May 23.

PMID:
21599822
19.

Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases.

Body JJ, Lichinitser M, Tjulandin S, Garnero P, Bergström B.

Ann Oncol. 2007 Jul;18(7):1165-71. Epub 2007 Apr 17. Erratum in: Ann Oncol. 2008 Mar;19(3):601.

20.

Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination.

Giuliano M, Giordano A, Jackson S, De Giorgi U, Mego M, Cohen EN, Gao H, Anfossi S, Handy BC, Ueno NT, Alvarez RH, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M.

Breast Cancer Res. 2014 Sep 16;16(5):440. doi: 10.1186/s13058-014-0440-8.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk